EN DE
Watch Genetics Generation Advancement Corp. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genetics Generation Advancement Corp. (4160) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Genetics Generation Advancement Corp. stock TWD 15.90, price TWD 33.40, that is 52.4% below the price, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

GG Genetics Generation Advancement Corp. logo Some data Nov 4, 2026

Genetics Generation Advancement Corp.

4160 · TWO
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Profit last quarter +188% vs. a year ago.
Expensive Growth (revenue 3y +3.3 %/yr in TWD)
Thin margins · 2.9% net margin (TTM)
Some data
Fair value 15.90 TWD · Strongly overvalued
Quality 38/100
Negative free cash flow
Trails peers (4/12)
Narrow moat 23/100 · thin data
Watch Genetics Generation Advancement Corp. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

159.57 TWD 18.87 TWD Fair Value 15.90 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 18.87 TWD – 159.57 TWD · fair‑value band 12.59 TWD – 18.45 TWD · the 33.40 TWD price screens above the 15.90 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Genetics Generation Advancement in your weekly email

Every Wednesday you see whether Genetics Generation Advancement is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genetics Generation Advancement Corp. provides genetic testing, molecular and science diagnostics, biotechnology, precision health, and digital innovation services in Taiwan.

Show moreShow less

The company offers testing services, including pre-implantation, prenatal, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology testing, and neonatology and pediatrics testing, as well as gastroenterology, hepatology, oncology, and medical research services.

It also provides bioinformatic, materials sciences, research and development management, enterprise quality management, process production operation, and e-submission products.

The company was formerly known as Genesis Genetics Asia Corp. and changed its name to Genetics Generation Advancement Corp. in February 2016. Genetics Generation Advancement Corp. was founded in 2008 and is based in Taipei City, Taiwan.

Stock analysis

Genetics Generation Advancement Corp. (4160) currently trades at 33.40 TWD, while our model-based Fair Value estimate is 15.90 TWD, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 23.84 TWD per share, and 1 of the 15 models we run sit above the 33.40 TWD price.

Bear case: the Earnings-Based group reads lowest at 6.36 TWD, and 14 of the 15 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 12.59 TWD (bear) to 18.45 TWD (bull), the price of 33.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Genetics Generation Advancement Corp. reported revenue of 603M TWD in FY2025 versus 520M TWD in FY2021, a compound +3.8%/yr. Reported net income was 21.4M TWD in FY2025, compounding +28.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 938M TWD (≈ $28.6M) Micro · P/E ratio 51.4 · P/S ratio 1.53 · EPS (TTM) 0.6500 TWD · Dividend yield 4.9% · Net margin 2.9% · Return on equity 3.7% · Return on assets (EBIT) 3.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −52%, 4160 screens richer than that median.

Fair Value models

Bear 12.59 TWD Fair Value 15.90 TWD Bull 18.45 TWD
Price 33.40 TWD · Downside -52.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5574 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 15.96 TWD 15.90 TWD 16.36 TWD 73
EPV 5.78 TWD 6.36 TWD 6.86 TWD 68
ROIC Compounder 5.78 TWD 6.36 TWD 6.86 TWD 67
All 15 models by family
Earnings-Based
Graham-Dodd 5.19 TWD 10.97 TWD 13.90 TWD 63
PEG = 1.0 1.66 TWD 2.37 TWD 3.07 TWD 55
EPV 5.78 TWD 6.36 TWD 6.86 TWD 68
Dividend Discount
Gordon GGM 16.17 TWD 24.54 TWD 33.50 TWD 65
DDM Multi-Stage 16.17 TWD 23.14 TWD 31.09 TWD 64
Multiples
P/E Multiple 12.59 TWD 16.78 TWD 20.98 TWD 63
P/S Multiple 9.73 TWD 12.97 TWD 16.21 TWD 58
P/B Multiple 72.47 TWD 96.63 TWD 120.79 TWD 55
EV/EBIT 5.64 TWD 7.58 TWD 9.52 TWD 63
EV/EBITDA 14.13 TWD 18.90 TWD 23.68 TWD 64
EV/Revenue 3.97 TWD 5.75 TWD 7.54 TWD 51
Asset-Based
NCAV (Graham) 9.74 TWD 14.76 TWD 18.45 TWD 52
Economic Profit
Residual Income 15.96 TWD 15.90 TWD 16.36 TWD 73
ROIC Compounder 5.78 TWD 6.36 TWD 6.86 TWD 67
Growth Earnings
Growth-Adj P/E 9.23 TWD 13.19 TWD 17.14 TWD 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+27.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.2%
Dividend (yield on the price)4.9%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 2%

4160 screens overvalued: fair value 52% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Genetics Generation Advancement Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −52.4% · Below median
Profitability
Return on equity (12 months) 3.7% · Below median
Return on assets 2.7% · Above median
Net margin (12 months) 2.9% · Below median
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 3.7% · Below median
Dividend yield (12 months) 4.9% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 51.4× · Priciest 25%
P/B 1.56× · Cheaper than median
P/S (12 months) 1.53× · Cheapest 25%
EV/EBITDA 45.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)19 · sector 39
PAST (return on equity)15 · sector 15
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)97 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs 4160
IQVIA Holdings IQV $271.83 $299.01 +10% vs 4160
Illumina, Inc ILMN $213.13 $234.44 +10% vs 4160
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 4160
Danaher Corporation DHR $230.25 $209.18 −9% vs 4160
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 4160
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 4160
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 4160
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs 4160
Waters Corporation WAT $457.60 $91.26 −80% vs 4160

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genetics Generation Advancement Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genetics Generation Advancement Corp. Fair Value". https://www.fairvalue-calculator.com/stock/4160

Frequently asked questions

Is Genetics Generation Advancement Corp. (4160) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 15.90 TWD versus a price of 33.40 TWD, about 52% lower (overvalued).
What is the fair value of 4160?
Our model-based fair value for Genetics Generation Advancement Corp. is 15.90 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 33.40 TWD.
What is the quality score of 4160?
Genetics Generation Advancement Corp. has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genetics Generation Advancement Corp. (4160)?
Our model-based price target is the fair value of 15.90 TWD (as of Nov 4, 2026) from 15 valuation models. Cautious scenario 12.59 TWD, optimistic scenario 18.45 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Genetics Generation Advancement Corp. stock forecast for 2026?
Our models put fair value at 15.90 TWD, about 52% lower versus a price of 33.40 TWD (overvalued). Cautious scenario 12.59 TWD, optimistic scenario 18.45 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Genetics Generation Advancement Corp. (4160)?
Genetics Generation Advancement Corp. reported trailing-twelve-month revenue of about 614M TWD (latest available figure, as of Nov 4, 2026).
Does Genetics Generation Advancement Corp. pay a dividend?
Genetics Generation Advancement Corp. currently shows a dividend yield of 4.87% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Genetics Generation Advancement Corp. (4160)?
Genetics Generation Advancement Corp. has a dividend yield of 4.9%.
What is the intrinsic value of Genetics Generation Advancement Corp. (4160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genetics Generation Advancement Corp. it is 15.90 TWD per share (as of Nov 4, 2026), against a price of 33.40 TWD. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Genetics Generation Advancement Corp. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 4160 trades above its calculated fair value: price 33.40 TWD, fair value 15.90 TWD, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4160?
No. The price is what the market pays today (33.40 TWD); the fair value is what the company's own numbers justify (15.90 TWD). For Genetics Generation Advancement Corp. the two are 17.50 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Genetics Generation Advancement Corp. worth?
The market values Genetics Generation Advancement Corp. at about 938M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 33.40 TWD; our models calculate a fair value of 15.90 TWD per share.
What do the bullish and bearish scenarios say about 4160?
Our models span a range for Genetics Generation Advancement Corp.: cautious scenario 12.59 TWD, base 15.90 TWD, optimistic 18.45 TWD per share (as of Nov 4, 2026, price 33.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4160?
Genetics Generation Advancement Corp. trades at a price-to-earnings ratio of 51.4 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 15.90 TWD is built from several models across several years. Other multiples: P/B 1.6, P/S 1.5, EV/EBITDA 45.8.
How solid is the balance sheet of Genetics Generation Advancement Corp. (4160)?
Balance-sheet figures for Genetics Generation Advancement Corp. (as of Nov 4, 2026): return on equity 3.7%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 4160 from its 52-week high?
Genetics Generation Advancement Corp. trades at 33.40 TWD, about 37% below its 52-week high of 53.07 TWD and at the low of 33.40 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 15.90 TWD is for.
Which stocks are comparable to Genetics Generation Advancement Corp.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genetics Generation Advancement Corp. stock attractive at the current price?
The data as of Nov 4, 2026: price 33.40 TWD, calculated fair value 15.90 TWD (−52%), Quality Score 38/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4160 calculated?
We run Genetics Generation Advancement Corp. through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 15.90 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genetics Generation Advancement Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genetics Generation Advancement Corp. (4160)?
The closing price on Nov 6, 2026 was 33.40 TWD. Our model-based fair value is 15.90 TWD, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genetics Generation Advancement Corp. right now?
The price sits above even our optimistic bull case (18.45 TWD). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Genetics Generation Advancement Corp.

How large is the market capitalisation of Genetics Generation Advancement Corp. (4160)?
The market capitalisation of Genetics Generation Advancement Corp. is 938M TWD (≈ $28.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genetics Generation Advancement Corp. (4160)?
The price-to-sales ratio of Genetics Generation Advancement Corp. is 1.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genetics Generation Advancement Corp. (4160)?
Earnings per share at Genetics Generation Advancement Corp. are 0.6500 TWD (price ÷ EPS = P/E 51.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genetics Generation Advancement Corp. (4160)?
The dividend yield of Genetics Generation Advancement Corp. is 4.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genetics Generation Advancement Corp. (4160)?
The net margin of Genetics Generation Advancement Corp. is 2.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genetics Generation Advancement Corp. (4160)?
The return on equity (ROE) of Genetics Generation Advancement Corp. is 3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genetics Generation Advancement Corp. (4160)?
On an EBIT basis the return on assets of Genetics Generation Advancement Corp. is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genetics Generation Advancement Corp. (4160)?
The operating margin of Genetics Generation Advancement Corp. is 0.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genetics Generation Advancement Corp. (4160)?
Revenue at Genetics Generation Advancement Corp. is growing +3.7% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genetics Generation Advancement Corp. (4160)?
Earnings per share at Genetics Generation Advancement Corp. are growing +188% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Genetics Generation Advancement Corp. (4160) generate?
The free cash flow of Genetics Generation Advancement Corp. is −49.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genetics Generation Advancement Corp. (4160) carry?
The net debt of Genetics Generation Advancement Corp. is 5.2M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genetics Generation Advancement Corp. in the live analysis

One click puts Genetics Generation Advancement Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.